OTC: CLRPF - Clarity Pharmaceuticals Ltd

半年間の収益性: -20.21%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール Clarity Pharmaceuticals Ltd


会社について Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2.

さらに詳しく
The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://www.claritypharmaceuticals.com
Цена ао 5.55
1日あたりの価格変動: +16.59% (2.32)
週ごとの価格変動: -7.99% (2.94)
月ごとの料金変更: -30.48% (3.891)
3ヶ月間の価格変動: -54.35% (5.925)
半年間の価格変動: -20.21% (3.39)
年間の価格変動: +109.69% (1.29)
3年間の価格推移: 0% (2.705)
5年間の価格推移: 0% (2.705)
10年間の価格推移: 0% (2.705)
年初からの価格変動: -43.3% (4.771)

過小評価

名前 意味 学年
P/S 0 0
P/BV 10.16 1
P/E 0 0
EV/EBITDA 0 0
合計: 2.63

効率

名前 意味 学年
ROA, % -31.35 0
ROE, % -33.85 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA 0 10
合計: 10

成長の衝動

名前 意味 学年
収益性 Revenue, % 0 0
収益性 Ebitda, % 0 0
収益性 EPS, % 1.72 1
合計: 4.2

機関 音量 共有, %
PFM Multi Manager Series-International Equity Fd 24827 0.01



スーパーバイザー 役職 支払い 生年
Dr. Alan John Taylor Ph.D. Executive Chairman 567.72k
Dr. Colin David Biggin Ph.D. MD, CEO & Executive Director 455.18k
Mr. David K. Green BEc., CA Chief Financial Officer 159.32k
Mr. Shaemus Gleason Executive Vice President of Operations N/A
Dr. Matthew Harris BSc., M.B.A., Ph.D. Chief Scientific Officer 130.94k
Michelle Parker Chief Clinical Officer N/A
Mr. Robert Vickery Company Secretary 109.28k
Ms. Lisa Sadetskaya Director of Corporate Communications.
Mary Bennett Head of Human Resource
Dr. Othon Gervasio Chief Medical Officer

住所: Australia, Sydney, National Innovation Centre - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.claritypharmaceuticals.com